कंपनी का अवलोकन
Barinthus Biotherapeutics plc is a biotechnology entity focused on the research, development, and commercialization of immunotherapies and vaccines within the United States and United Kingdom markets. The company specifically develops VTP-1000, which serves as an antigen-specific immune tolerance candidate currently progressing through Phase I clinical trials. Operating within the broader healthcare sector and the specialized biotechnology industry, this firm represents a micro-cap entity with a market capitalization of $22.47M and an employee base consisting of 14 individuals. The combination of a market cap under $25 million and the absence of reported annual revenue indicates that the company is in an early-stage developmental phase where capital is primarily allocated toward R&D rather than commercial operations.
वित्तीय स्वास्थ्य
The company reports a net income of $-66,428,000 and an EBITDA of $-55,223,000, while annual revenue figures are not available for reporting. The substantial gap between reported net income and EBITDA highlights a significant negative impact from non-operating expenses or tax-related adjustments, which is typical for pre-revenue biotechnology firms. Free cash flow stands at $-28,044,376, indicating that the company is burning cash to fund its research pipeline rather than generating operational cash flow. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, reflecting a business model where revenue generation has not yet outpaced the high fixed costs associated with drug development. The balance sheet holds $70.46M in cash against $11.28M in debt, resulting in a debt-to-equity ratio of 15.19, which suggests a highly leveraged structure relative to equity but one supported by a large cash reserve. The current ratio is 7.76, demonstrating robust short-term liquidity as the company possesses more than seven times the current assets necessary to cover its current liabilities. Return on Equity is -65.0% and Return on Assets is -28.1%, metrics that reveal the company is currently destroying shareholder value and utilizing assets to generate losses, a condition expected during the high-burn pre-commercialization stage of biotechnology.
मूल्यांकन आकलन
The trailing twelve-month P/E ratio is listed as N/A, while the forward P/E is reported as -0.48, implying that earnings are currently negative and traditional valuation multiples based on profitability are not applicable. The price-to-book ratio is 0.30, indicating that the market values the company at only 30% of its book value, which suggests a deep discount relative to the asset base or reflects significant uncertainty regarding future commercial success. The price-to-sales ratio is N/A and the EV/EBITDA stands at 0.66, suggesting that valuation is being assessed primarily through enterprise value relative to earnings before interest, taxes, depreciation, and amortization despite the negative earnings profile. The 52-week high is $2.92 and the 52-week low is $0.51, placing the current trading range within a volatile band that spans nearly six times in magnitude. The beta value is -0.60, which indicates an inverse relationship to the broader market and suggests that the stock's price movements are negatively correlated with general market trends, adding a unique layer of volatility distinct from standard biotechnology peers.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, precluding any analysis of historical growth rates or comparisons between earnings and revenue expansion. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, meaning all available cash is retained for reinvestment into research and development rather than distributed to shareholders. The absence of dividend payments aligns with the company's lifecycle stage, where capital preservation and pipeline advancement take precedence over income generation for investors. The overall growth and income profile is characterized by zero current earnings growth and zero dividend income, reflecting a capital-intensive strategy typical of early-stage biotechnology firms seeking to commercialize their immunotherapy candidates.